Anaptysbio (ANAB) Gains from Sales and Divestitures (2025 - 2026)

Anaptysbio (ANAB) reported Gains from Sales and Divestitures of $34300.0 for Q1 2026, down 90.36% quarter-over-quarter from $355627.0 in Q4 2025.

Anaptysbio (ANAB) Gains from Sales and Divestitures (2025 - 2026) Analysis & Trends

Anaptysbio has reported Gains from Sales and Divestitures for 2 years, with the latest figure at $34300.0 in Q1 2026.

For the quarter ending Q1 2026, Gains from Sales and Divestitures changed N/A year-over-year to $34300.0; the trailing twelve-month figure through Mar 2026 stood at $34300.0 (changed N/A YoY), and the FY2025 full-year result was $355627.0, changed N/A from the prior year.
Gains from Sales and Divestitures for Q1 2026 stood at $34300.0, down from $355627.0 in the prior quarter.
The five-year high for Gains from Sales and Divestitures was $355627.0 in Q4 2025, with the low at $34300.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Anaptysbio	1.66 Bn	1.38 Bn	-

Download Data